AR095631A1 - Composición farmacéutica que comprende un activador ampk y un agente de serotonergico y métodos de uso - Google Patents
Composición farmacéutica que comprende un activador ampk y un agente de serotonergico y métodos de usoInfo
- Publication number
- AR095631A1 AR095631A1 ARP140101258A ARP140101258A AR095631A1 AR 095631 A1 AR095631 A1 AR 095631A1 AR P140101258 A ARP140101258 A AR P140101258A AR P140101258 A ARP140101258 A AR P140101258A AR 095631 A1 AR095631 A1 AR 095631A1
- Authority
- AR
- Argentina
- Prior art keywords
- serotonin
- pharmaceutical composition
- adiponectin
- group
- agent
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 7
- 239000003795 chemical substances by application Substances 0.000 title abstract 5
- MPLLLQUZNJSVTK-UHFFFAOYSA-N 5-[3-[4-[2-(4-fluorophenyl)ethoxy]phenyl]propyl]furan-2-carboxylic acid Chemical compound O1C(C(=O)O)=CC=C1CCCC(C=C1)=CC=C1OCCC1=CC=C(F)C=C1 MPLLLQUZNJSVTK-UHFFFAOYSA-N 0.000 title abstract 4
- 230000000862 serotonergic effect Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 9
- 108010076365 Adiponectin Proteins 0.000 abstract 6
- 102000011690 Adiponectin Human genes 0.000 abstract 5
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 abstract 4
- -1 coripalmin Chemical compound 0.000 abstract 4
- 239000003112 inhibitor Substances 0.000 abstract 4
- 229940076279 serotonin Drugs 0.000 abstract 4
- 229940123464 Thiazolidinedione Drugs 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- WTOYNNBCKUYIKC-JMSVASOKSA-N (+)-nootkatone Chemical compound C1C[C@@H](C(C)=C)C[C@@]2(C)[C@H](C)CC(=O)C=C21 WTOYNNBCKUYIKC-JMSVASOKSA-N 0.000 abstract 2
- AEQDJSLRWYMAQI-QGZVFWFLSA-N (13ar)-2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5h-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3C[C@@H]2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-QGZVFWFLSA-N 0.000 abstract 2
- RTRQQBHATOEIAF-UHFFFAOYSA-N AICA riboside Natural products NC1=C(C(=O)N)N=CN1C1C(O)C(O)C(CO)O1 RTRQQBHATOEIAF-UHFFFAOYSA-N 0.000 abstract 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 abstract 2
- 102100022204 DNA-dependent protein kinase catalytic subunit Human genes 0.000 abstract 2
- 101710157074 DNA-dependent protein kinase catalytic subunit Proteins 0.000 abstract 2
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 abstract 2
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 2
- DYYZXRCFCVDSKD-UHFFFAOYSA-N N6,N6-dimethyl-N4-[1-(phenylmethyl)-5-indazolyl]pyrido[3,4-d]pyrimidine-4,6-diamine Chemical compound N1=CN=C2C=NC(N(C)C)=CC2=C1NC(C=C1C=N2)=CC=C1N2CC1=CC=CC=C1 DYYZXRCFCVDSKD-UHFFFAOYSA-N 0.000 abstract 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 abstract 2
- 102100026715 Serine/threonine-protein kinase STK11 Human genes 0.000 abstract 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 abstract 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 abstract 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 2
- RTRQQBHATOEIAF-UUOKFMHZSA-N acadesine Chemical compound NC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RTRQQBHATOEIAF-UUOKFMHZSA-N 0.000 abstract 2
- XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 abstract 2
- 229960004111 buformin Drugs 0.000 abstract 2
- 239000000039 congener Substances 0.000 abstract 2
- WTOYNNBCKUYIKC-UHFFFAOYSA-N dl-nootkatone Natural products C1CC(C(C)=C)CC2(C)C(C)CC(=O)C=C21 WTOYNNBCKUYIKC-UHFFFAOYSA-N 0.000 abstract 2
- 230000007062 hydrolysis Effects 0.000 abstract 2
- 238000006460 hydrolysis reaction Methods 0.000 abstract 2
- 229960003987 melatonin Drugs 0.000 abstract 2
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 abstract 2
- 239000002207 metabolite Substances 0.000 abstract 2
- 229960003105 metformin Drugs 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- OPGPFZQBCIAFLI-UHFFFAOYSA-N obovatol Chemical compound OC1=CC(CC=C)=CC(OC=2C=CC(CC=C)=CC=2)=C1O OPGPFZQBCIAFLI-UHFFFAOYSA-N 0.000 abstract 2
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 abstract 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 abstract 2
- 239000002243 precursor Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 239000000047 product Substances 0.000 abstract 2
- 229940016667 resveratrol Drugs 0.000 abstract 2
- 235000021283 resveratrol Nutrition 0.000 abstract 2
- 229960004586 rosiglitazone Drugs 0.000 abstract 2
- 239000000952 serotonin receptor agonist Substances 0.000 abstract 2
- 239000003772 serotonin uptake inhibitor Substances 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 150000001467 thiazolidinediones Chemical class 0.000 abstract 2
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 abstract 1
- IORPHWDBRHOADK-ZWKOTPCHSA-N (6r)-6-[(1s)-7-hydroxy-6-methoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl]-6h-furo[3,4-g][1,3]benzodioxol-8-one Chemical compound O([C@H]1[C@H]2N(C)CCC=3C=C(C(=CC=32)O)OC)C(=O)C2=C1C=CC1=C2OCO1 IORPHWDBRHOADK-ZWKOTPCHSA-N 0.000 abstract 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 abstract 1
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical compound OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 abstract 1
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 abstract 1
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 abstract 1
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 abstract 1
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 abstract 1
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 abstract 1
- 102000016912 Aldehyde Reductase Human genes 0.000 abstract 1
- 108010053754 Aldehyde reductase Proteins 0.000 abstract 1
- KPSRODZRAIWAKH-JTQLQIEISA-N Ciprofibrate Natural products C1=CC(OC(C)(C)C(O)=O)=CC=C1[C@H]1C(Cl)(Cl)C1 KPSRODZRAIWAKH-JTQLQIEISA-N 0.000 abstract 1
- 108010006124 DNA-Activated Protein Kinase Proteins 0.000 abstract 1
- 102000005768 DNA-Activated Protein Kinase Human genes 0.000 abstract 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 abstract 1
- BYTORXDZJWWIKR-UHFFFAOYSA-N Hinokiol Natural products CC(C)c1cc2CCC3C(C)(CO)C(O)CCC3(C)c2cc1O BYTORXDZJWWIKR-UHFFFAOYSA-N 0.000 abstract 1
- 101000628562 Homo sapiens Serine/threonine-protein kinase STK11 Proteins 0.000 abstract 1
- 102000016267 Leptin Human genes 0.000 abstract 1
- 108010092277 Leptin Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 101710181599 Serine/threonine-protein kinase STK11 Proteins 0.000 abstract 1
- AEQDJSLRWYMAQI-UHFFFAOYSA-N Tetrahydropalmatine Natural products C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 abstract 1
- PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000003420 antiserotonin agent Substances 0.000 abstract 1
- 229960000516 bezafibrate Drugs 0.000 abstract 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000003197 catalytic effect Effects 0.000 abstract 1
- 150000001765 catechin Chemical class 0.000 abstract 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 abstract 1
- 235000005487 catechin Nutrition 0.000 abstract 1
- 229960002174 ciprofibrate Drugs 0.000 abstract 1
- KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 abstract 1
- 229960001214 clofibrate Drugs 0.000 abstract 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 abstract 1
- 229940108924 conjugated linoleic acid Drugs 0.000 abstract 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 1
- 229960002297 fenofibrate Drugs 0.000 abstract 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 abstract 1
- 229940125753 fibrate Drugs 0.000 abstract 1
- 229960003627 gemfibrozil Drugs 0.000 abstract 1
- FVYXIJYOAGAUQK-UHFFFAOYSA-N honokiol Chemical compound C1=C(CC=C)C(O)=CC=C1C1=CC(CC=C)=CC=C1O FVYXIJYOAGAUQK-UHFFFAOYSA-N 0.000 abstract 1
- VVOAZFWZEDHOOU-UHFFFAOYSA-N honokiol Natural products OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 abstract 1
- 229940039781 leptin Drugs 0.000 abstract 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 abstract 1
- 229960004329 metformin hydrochloride Drugs 0.000 abstract 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- JTSLALYXYSRPGW-UHFFFAOYSA-N n-[5-(4-cyanophenyl)-1h-pyrrolo[2,3-b]pyridin-3-yl]pyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NC(C1=C2)=CNC1=NC=C2C1=CC=C(C#N)C=C1 JTSLALYXYSRPGW-UHFFFAOYSA-N 0.000 abstract 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 abstract 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 abstract 1
- 229960005095 pioglitazone Drugs 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 230000009103 reabsorption Effects 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 229960003271 rosiglitazone maleate Drugs 0.000 abstract 1
- SUFUKZSWUHZXAV-BTJKTKAUSA-N rosiglitazone maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O SUFUKZSWUHZXAV-BTJKTKAUSA-N 0.000 abstract 1
- 230000013275 serotonin uptake Effects 0.000 abstract 1
- 239000000021 stimulant Substances 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pregnancy & Childbirth (AREA)
- AIDS & HIV (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361793407P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR095631A1 true AR095631A1 (es) | 2015-10-28 |
Family
ID=51538303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140101258A AR095631A1 (es) | 2013-03-15 | 2014-03-17 | Composición farmacéutica que comprende un activador ampk y un agente de serotonergico y métodos de uso |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20140350064A1 (https=) |
| EP (1) | EP2983473A4 (https=) |
| JP (1) | JP2016513734A (https=) |
| KR (1) | KR20160005341A (https=) |
| CN (1) | CN105636438A (https=) |
| AR (1) | AR095631A1 (https=) |
| AU (1) | AU2014227807B2 (https=) |
| BR (1) | BR112015023922A2 (https=) |
| CA (1) | CA2909633A1 (https=) |
| CL (1) | CL2015002680A1 (https=) |
| HK (1) | HK1222297A1 (https=) |
| IL (1) | IL241587B (https=) |
| MX (1) | MX2015012760A (https=) |
| RU (1) | RU2015143438A (https=) |
| TW (1) | TW201444552A (https=) |
| WO (1) | WO2014144130A2 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180071269A1 (en) * | 2015-08-12 | 2018-03-15 | Tianxin Wang | Therapeutical methods, formulations and nutraceutical formulations |
| ES2567105B1 (es) * | 2014-09-19 | 2017-02-10 | Consejo Superior De Investigaciones Científicas (Csic) | Derivados de indol para la prevención y/o tratamiento de diabetes ytrastornos metabólicos relacionados |
| WO2016126662A1 (en) * | 2015-02-03 | 2016-08-11 | Kardiatonos, Inc. | Compounds for the prevention and treatment of vascular disease |
| WO2016200726A1 (en) * | 2015-06-08 | 2016-12-15 | Texas Tech University System | Inhibitors of mci-1 as drugs to overcome resistance to braf inhibitors and mek inhibitors |
| WO2017018752A1 (ko) * | 2015-07-29 | 2017-02-02 | 고려대학교 산학협력단 | 부스피론 유도체 및 이를 함유하는 약학 조성물 |
| KR101663543B1 (ko) * | 2015-07-29 | 2016-10-07 | 고려대학교 산학협력단 | 부스피론 유도체 및 이를 함유하는 약학 조성물 |
| US10357466B2 (en) * | 2015-08-01 | 2019-07-23 | Stephen J. Petti | Compositions and methods for combination pharmacological treatments to induce a prolonged, mild decrease in core body temperature |
| CN105541665A (zh) * | 2016-02-18 | 2016-05-04 | 江苏大学 | 一种抗肿瘤药物化合物及制备方法和应用 |
| KR101838622B1 (ko) * | 2016-09-20 | 2018-03-14 | 김브라이언 | 아디포넥틴 수용체에 대한 작용제 펩타이드 |
| US11040935B2 (en) | 2016-10-05 | 2021-06-22 | University of Pittsburgh—of the Commonwealth System of Higher Education | Small molecule AMPK activators |
| WO2018115010A1 (en) | 2016-12-20 | 2018-06-28 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene |
| ES2769286T3 (es) | 2016-12-20 | 2020-06-25 | Lts Lohmann Therapie Systeme Ag | Sistema terapéutico transdérmico que contiene asenapina |
| ES2881783T3 (es) | 2017-06-26 | 2021-11-30 | Lts Lohmann Therapie Systeme Ag | Sistema terapéutico transdérmico que contiene asenapina y polímero de acrílico y silicona |
| CN107252425A (zh) * | 2017-07-12 | 2017-10-17 | 上海华堇生物技术有限责任公司 | 去氢延胡索素的药物用途 |
| MA50786A (fr) * | 2017-10-26 | 2022-04-27 | Blumentech S L | Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques |
| US11103465B2 (en) | 2017-11-22 | 2021-08-31 | Ted's Brain Science, Inc. | Trans-resveratrol topical medication for the treatment of pain and method of manufacture thereof |
| US11208475B1 (en) * | 2018-01-30 | 2021-12-28 | Flagship Pioneering Innovations V, Inc. | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using serotonin receptor activators |
| CN108159044A (zh) * | 2018-02-26 | 2018-06-15 | 华中科技大学 | 抗坏血酸与二甲双胍的复合制剂用于制备化疗药物的应用 |
| CN112533593A (zh) | 2018-06-20 | 2021-03-19 | 罗曼治疗系统股份公司 | 含有阿塞那平的透皮治疗系统 |
| CA3101420A1 (en) | 2018-06-20 | 2019-12-26 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| CN111960970B (zh) * | 2018-08-08 | 2021-08-20 | 中国人民解放军总医院 | 抗肿瘤化合物 |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| CN109771424B (zh) * | 2019-03-11 | 2021-03-16 | 马慧 | 一种防治老年ⅱ型糖尿病性骨质疏松症的药物组合物及其应用 |
| CN109793727A (zh) * | 2019-03-13 | 2019-05-24 | 湖北科技学院 | 一种有效抗恶性肿瘤的药物组合物及其应用 |
| EP4027987A4 (en) | 2019-09-10 | 2023-11-29 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Methods and materials for increasing level of phosphorylated ampk protein |
| CN110559298A (zh) * | 2019-10-28 | 2019-12-13 | 中国药科大学 | 一种天然化合物Egenine用于制备抗肾纤维化药物的用途 |
| AU2020372682A1 (en) * | 2019-10-31 | 2022-06-09 | Jd Bioscience Inc. | Tricyclic compound and pharmaceutical use thereof |
| KR20240096817A (ko) | 2020-05-19 | 2024-06-26 | 사이빈 아이알엘 리미티드 | 중수소화된 트립타민 유도체 및 사용 방법 |
| CN114728933B (zh) * | 2020-07-22 | 2023-06-16 | 山东绿叶制药有限公司 | 5-ht2a受体抑制剂或反向激动剂及其制备方法和应用 |
| US20240208923A1 (en) | 2021-03-10 | 2024-06-27 | Jnana Therapeutics Inc. | Small molecule inhibitors of mammalian slc6a19 function |
| CA3225133A1 (en) | 2021-07-07 | 2023-01-12 | Matthew Alexander James Duncton | N,n-dimethyltryptamine and related psychedlics and uses thereof |
| EP4429672A4 (en) | 2021-11-12 | 2025-04-30 | Terran Biosciences Inc. | PSILOCYBIN AND O-ACETYLPSILOCIN, SALTS AND SOLID FORMS THEREOF |
| WO2024123824A1 (en) * | 2022-12-05 | 2024-06-13 | Enveda Therapeutics, Inc. | Nootkatone for the treatment of pruritus |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3174901A (en) * | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
| US20070244202A1 (en) * | 2004-06-28 | 2007-10-18 | Kao Corporation | Ampk Activator |
| US20070149466A1 (en) * | 2005-07-07 | 2007-06-28 | Michael Milburn | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
| US7754700B2 (en) * | 2006-04-24 | 2010-07-13 | Trager Seymour F | Composition and methods for alleviating symptoms of neurotoxicity |
| CA2675638C (en) * | 2007-01-16 | 2015-11-24 | Ipintl, Llc | Composition comprising serotonin for treating metabolic syndrome |
| US20120183600A1 (en) * | 2007-01-16 | 2012-07-19 | Chien-Hung Chen | Novel composition for treating metabolic syndrome and other conditions |
| WO2011112167A1 (en) * | 2009-03-13 | 2011-09-15 | Reset Therapeutics, Inc. | Compositions and methods for diabetes treatment |
| US8486922B2 (en) * | 2010-04-28 | 2013-07-16 | Chien-Hung Chen | Composition |
-
2014
- 2014-03-14 EP EP14763798.7A patent/EP2983473A4/en not_active Withdrawn
- 2014-03-14 JP JP2016502780A patent/JP2016513734A/ja active Pending
- 2014-03-14 CA CA2909633A patent/CA2909633A1/en not_active Abandoned
- 2014-03-14 AU AU2014227807A patent/AU2014227807B2/en not_active Ceased
- 2014-03-14 RU RU2015143438A patent/RU2015143438A/ru unknown
- 2014-03-14 BR BR112015023922A patent/BR112015023922A2/pt not_active IP Right Cessation
- 2014-03-14 US US14/212,734 patent/US20140350064A1/en not_active Abandoned
- 2014-03-14 MX MX2015012760A patent/MX2015012760A/es unknown
- 2014-03-14 CN CN201480028057.0A patent/CN105636438A/zh active Pending
- 2014-03-14 KR KR1020157029838A patent/KR20160005341A/ko not_active Withdrawn
- 2014-03-14 WO PCT/US2014/028413 patent/WO2014144130A2/en not_active Ceased
- 2014-03-14 TW TW103109748A patent/TW201444552A/zh unknown
- 2014-03-14 HK HK16109576.5A patent/HK1222297A1/zh unknown
- 2014-03-17 AR ARP140101258A patent/AR095631A1/es unknown
-
2015
- 2015-09-14 CL CL2015002680A patent/CL2015002680A1/es unknown
- 2015-09-16 IL IL241587A patent/IL241587B/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2983473A2 (en) | 2016-02-17 |
| WO2014144130A3 (en) | 2015-02-05 |
| BR112015023922A2 (pt) | 2017-07-18 |
| TW201444552A (zh) | 2014-12-01 |
| IL241587B (en) | 2019-01-31 |
| AU2014227807A1 (en) | 2015-11-05 |
| AU2014227807B2 (en) | 2018-03-08 |
| CN105636438A (zh) | 2016-06-01 |
| KR20160005341A (ko) | 2016-01-14 |
| US20140350064A1 (en) | 2014-11-27 |
| CL2015002680A1 (es) | 2016-09-02 |
| WO2014144130A2 (en) | 2014-09-18 |
| HK1222297A1 (zh) | 2017-06-30 |
| EP2983473A4 (en) | 2016-11-23 |
| JP2016513734A (ja) | 2016-05-16 |
| RU2015143438A (ru) | 2017-04-21 |
| CA2909633A1 (en) | 2014-09-18 |
| MX2015012760A (es) | 2016-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR095631A1 (es) | Composición farmacéutica que comprende un activador ampk y un agente de serotonergico y métodos de uso | |
| UY38221A (es) | Inhibidores de proteínas ras con g12c mutantes | |
| BR112014025564B8 (pt) | composto heterocíclico contendo nitrogênio ou sal do mesmo, composição farmacêutica e uso da mesma | |
| MX2021005007A (es) | Inhibidores de cinasa 7 dependiente de ciclina (cdk7). | |
| UY33491A (es) | ?Derivados de sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina?. | |
| AR079208A2 (es) | Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica | |
| AR055076A1 (es) | Derivados de1,1-dioxido de 1,4-benzotiazepina,procedimiento para prepararlos,composiciones farmaceuticas que los contienen y usos en terapeutica. | |
| UY39027A (es) | Uso de favipiravir en el tratamiento de la infección por coronavirus | |
| AR072454A1 (es) | Composiciones que comprenden aspirina, metformina y clorhidrato de serotonina y metodos para el tratamiento de enfermedades hiperproliferativas | |
| UY38001A (es) | Compuestos que inhiben las proteínas ras mutantes g12c | |
| AR065837A1 (es) | Composicion para el tratamiento del sindrome metabolico | |
| UY33501A (es) | Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina | |
| AR093244A1 (es) | Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2 | |
| CR11119A (es) | Derivados de indazol oxadiazol sustituidos para uso como agonistas esfingozina 1-fosfato (sip) | |
| BR112016028814A2 (pt) | ?composição farmacêutica, métodos de tratamento de uma doença ou condição, de inibição de reações imunitárias ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, composto, um sal, um isômero, ou uma mistura farmaceuticamente aceitável do mesmo, e, uso de um composto, de um sal, de um isômero, ou de uma mistura farmaceuticamente aceitável do mesmo? | |
| UY30809A1 (es) | Derivados de n-[3-[4-fenil)piperidin-1-carbonil]fenil]sulfonamidas sustituidas, procesos de preparacion y aplicaciones | |
| AR049578A1 (es) | Derivados de hidantoina, procesos de obtencion y composiciones farmaceuticas | |
| BR112016028818A2 (pt) | composição farmacêutica, métodos de tratamento de uma doença ou condição, de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase e de inibição de reações imunes excessivas ou destrutivas ou crescimento ou proliferação de células cancerosas, kit, composto, sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo, e, uso de um composto, um sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo. | |
| DOP2016000250A (es) | Una forma amorfa y una cristalina de hemitartrato genz 112638 como inhibidor de glucosilceramida sintasa | |
| ES3059433T3 (en) | Solid forms and formulations of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide | |
| UY33500A (es) | Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina | |
| DOP2011000218A (es) | Derivados de sulfonamida | |
| AR064041A1 (es) | Derivados de 2,-5-dioxoimidazolin-n-pirimidin sustituidos inhibidores de metaloproteinasas de matriz(mnp), composiciones farmaceuticas que los contienen, proceso de preparacion y usos en diversos procesos inflamatorios. | |
| BR112016028876A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos. | |
| DOP2010000387A (es) | Compuestos pirazolicos 436 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |